Galmed Pharmaceuticals Ltd. (GLMD)

Nasdaq: GLMD · Pharmaceutical Preparations · Ramat Gan, IL · filing with the SEC since 2013

Full chart Alerts Compare

Grade4.1

◀ Past 4.5● Present 5.6▶ Future 2.6

4 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Galmed Pharmaceuticals Ltd.

Nine metrics read from its own filings, by tense

Headline grade

4.1/10

◀ Past4.525% of the headline

● Present5.635% of the headline

▶ Future2.640% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.5/1025% of the headline grade · 3 of 3 filed

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Galmed Pharmaceuticals Ltd.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

4.7/10

What has it actually done, year after year?

5 filed years; profitable in 1 of 5.

weight 45% of this tense · 47th percentile among 323 sector filers · read for its customers

From the record

Galmed Pharmaceuticals Ltd.'s 5 filed years say what it did: it rose in 2 of 3 years; the deepest fall was 100% from fiscal 2018 to fiscal 2019; net income was positive in 1 of 5 of those years (its annual reports).

What it rests on

the share of years revenue rosetop 41% of its family
the share of filed years with a profittop 27% of its family
the deepest fall from a revenue peak100.0%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

as filed

1.8/10

How has it treated the people who own it?

Share count grew 213.6% a year. 0% of cash flow returned. Insiders: 0 sales, 0 purchases.

weight 33% of this tense · 17th percentile among 80 sector filers · read for its shareholders

From the record

Over the 3 fiscal years to 2025-12-31, Galmed Pharmaceuticals Ltd.'s diluted share count grew about 213.6% a year, and dividends and buybacks returned about 0% of its net income over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

What it rests on

the share count over the yearsbottom 15% of its family
cash returned against operating cash flowbottom 20% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

● Present

What are they doing right now?

5.6/1035% of the headline grade · 1 of 3 filed, 2 estimated

Financial health

as filed

6.2/10

Is it financially healthy right now?

ROE 44%: 44¢ of profit per shareholder dollar. Leverage 15%: owes 15¢ per asset dollar.

weight 45% of this tense · 62nd percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Galmed Pharmaceuticals Ltd. earned about 44 cents of profit for every dollar of shareholders' money. Leverage: it owed about 15 cents per dollar of assets, and net share issuance: its share count grew 363.2% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 25% of its family
return on equitytop 2% of its family
the share count against the year beforebottom 13% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

SI estimate

5.2/10

How strong is its position in its industry?

SI estimate 5.2/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 315 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: No filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 315 members with one.
What the record cannot read: No filed revenue on file.
How it was reasoned: family median, 315 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Galmed Pharmaceuticals Ltd.'s industry position is put at 5.2 of 10 with a confidence of 20 of 100, because no filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 315 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Galmed Pharmaceuticals Ltd.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

2.6/1040% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

SI estimate

4.3/10

How much room does it have to grow?

SI estimate 4.3/10, confidence 35 of 100 (one part).

weight 33% of this tense · 43rd percentile among 479 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, cash less debt against assets, which ranks in the bottom 43% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read: The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned: one part: cash less debt against assets, the one part on file, ranked among 479 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Galmed Pharmaceuticals Ltd.'s room to expand is put at 4.3 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the bottom 43% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed

2.5/10

What could actually drive growth from here?

bottom 25% of 306 in its family for growth drivers.

weight 45% of this tense · 25th percentile among 306 sector filers · read for its customers

From the record

Galmed Pharmaceuticals Ltd.'s growth drivers, from the filed years to fiscal 2020: research spending grew -27.9% a year (bottom 14%); capital spending grew -30.7% a year (bottom 37%) (its annual reports). Galmed Pharmaceuticals Ltd. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth of research spending-27.9%bottom 14% of its family
three-year growth of capital spending-30.7%bottom 37% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate

0.3/10

Did its newest year beat what its own record pointed to?

SI estimate 0.3/10, confidence 35 of 100 (one part).

weight 22% of this tense · 3rd percentile among 284 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, net income against the prior three years' average, which ranks in the bottom 3% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: one part: net income against the prior three years' average, the one part on file, ranked among 284 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Galmed Pharmaceuticals Ltd.'s expectations vs reality is put at 0.3 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the bottom 3% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton GLMD · research, not advice